Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ: RXRX )

7.240 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today
Via Benzinga
Cathie Wood-Led Ark Invest Scoops Up $5.16M Worth Of Palantir Shares Amid Raging AI Fervor
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn’t Discovered Yet
Undiscovered biotech stocks can be risky but rewarding, especially when it involves mid-cap stocks with promise and no profit. 
Via InvestorPlace
Why Recursion Pharmaceuticals Stock Is Tumbling Thursday
Recursion announced that it intends to offer and sell 30,769,230 shares of its common stock for $6.50 per share in an underwritten public offering. The clinical-stage biotech company also said it plans... 
Via Benzinga
Levi Strauss Posts Mixed Results, Joins Walgreens, AeroVironment And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
How Is The Market Feeling About Recursion Pharmaceuticals?
Via Benzinga
3 AI Stocks on the Edge of a Massive Surge
Writers covering the AI stocks space agree on one thing: Nvidia’s dramatic rise is spawning a whole new wave of AI winners. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning! 
Via InvestorPlace
Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Pharmaceuticals Stock Is Diving Wednesday: What's Going On?
After the market close on Wednesday, Recursion said it intends to offer and sell $200 million worth of its common stock in an underwritten public offering. All of the shares are being offered by... 
Via Benzinga
Recursion Announces Proposed Offering of Class A Common Stock
From Recursion Pharmaceuticals
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Recursion Pharmaceuticals Stock Is Moving Tuesday: What's Happening?
Shares of clinical stage biotech company Recursion Pharmaceuticals Inc (NASDAQ:RXRX) are trading higher Tuesday. The company's CEO Chris Gibson joined CNBC for an interview ahead of a presentation with... 
Via Benzinga
What's Going On With Recursion Pharmaceuticals Stock Monday?
Recursion Pharmaceuticals shares traded higher Monday after the company provided updated guidance and partnership updates at its Investor Day. The stock is continuing to move higher after hours amid a... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
Via Talk Markets
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
The global 
Via Talk Markets
3 Stocks Under $10 Set to Quadruple by 2025: June Edition
Low-priced stocks under $10 can be explosively awarding if you spot the right one at the right time with the right catalyst. 
Via InvestorPlace
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
The global 
Via Talk Markets
Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim
The CEO has set a high bar for the business, and if it hits it, the stock could easily 10x in value. 
Via The Motley Fool
Nvidia’s Golden Handshake: 3 Stocks Reaping the Rewards of an NVDA Alliance
These Nvidia partner stocks stand to gain from the semiconductor's industry dominance, but they have plenty of upside of their own. 
Via InvestorPlace
1 Disruptive Biotech Stock to Buy Now, and 1 to Consider
Both of these companies could soon set the standard in their fields. 
Via The Motley Fool
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Cathie Wood Owns These 2 AI Stocks. Should You?
One looks like a solid option. The other one, not so much. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is Recursion Pharmaceuticals Stock a Millionaire-Maker?
Recursion Pharmaceuticals hopes to transform the healthcare industry with the help of AI. 
Via The Motley Fool
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity bias in... 
From Recursion Pharmaceuticals
Via GlobeNewswire
2 Cathie Wood Biotech Stocks That Could Be Worth the Risk
You don't need to buy her picks, but it's worth understanding them. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.